Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Director Ann M. Veneman sold 835 shares of Alexion Pharmaceuticals stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $145.81, for a total transaction of $121,751.35. Following the completion of the transaction, the director now owns 5,480 shares of the company’s stock, valued at approximately $799,038.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Alexion Pharmaceuticals, Inc. (ALXN) opened at 144.07 on Wednesday. The firm’s 50-day moving average is $137.20 and its 200-day moving average is $124.25. Alexion Pharmaceuticals, Inc. has a 1-year low of $96.18 and a 1-year high of $149.34. The company has a market cap of $32.15 billion, a PE ratio of 62.48 and a beta of 1.40.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.08 by $0.48. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. The company had revenue of $912.00 million during the quarter, compared to the consensus estimate of $846.15 million. During the same period in the previous year, the company posted $1.13 earnings per share. Alexion Pharmaceuticals’s revenue for the quarter was up 21.1% on a year-over-year basis. On average, equities analysts forecast that Alexion Pharmaceuticals, Inc. will post $5.61 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Insider Selling: Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Director Sells 835 Shares of Stock” was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://ledgergazette.com/2017/09/13/alexion-pharmaceuticals-inc-alxn-director-ann-m-veneman-sells-835-shares-of-stock.html.
A number of equities research analysts have recently weighed in on the stock. J P Morgan Chase & Co upgraded shares of Alexion Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $163.00 to $175.00 in a report on Tuesday, September 5th. BMO Capital Markets reissued an “outperform” rating and set a $173.00 price objective (up from $168.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday. SunTrust Banks, Inc. reaffirmed a “buy” rating and issued a $180.00 target price (up from $170.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday. Leerink Swann increased their price objective on shares of Alexion Pharmaceuticals from $136.00 to $170.00 and gave the company an “outperform” rating in a research report on Friday, July 28th. Finally, Zacks Investment Research raised shares of Alexion Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $158.00 price objective on the stock in a research report on Wednesday, August 2nd. Five research analysts have rated the stock with a hold rating, twenty have given a buy rating and three have given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $157.09.
A number of large investors have recently made changes to their positions in the business. Aldebaran Financial Inc. acquired a new position in Alexion Pharmaceuticals in the second quarter valued at approximately $426,000. Toronto Dominion Bank raised its stake in shares of Alexion Pharmaceuticals by 25.5% during the 2nd quarter. Toronto Dominion Bank now owns 76,071 shares of the biopharmaceutical company’s stock worth $9,254,000 after buying an additional 15,464 shares during the period. WINTON GROUP Ltd acquired a new position in shares of Alexion Pharmaceuticals during the 2nd quarter worth approximately $296,000. Public Employees Retirement System of Ohio raised its stake in shares of Alexion Pharmaceuticals by 1.6% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 151,163 shares of the biopharmaceutical company’s stock worth $18,392,000 after buying an additional 2,394 shares during the period. Finally, Wealthsource Partners LLC raised its stake in shares of Alexion Pharmaceuticals by 4.4% during the 2nd quarter. Wealthsource Partners LLC now owns 3,002 shares of the biopharmaceutical company’s stock worth $365,000 after buying an additional 126 shares during the period. 94.26% of the stock is owned by institutional investors.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.